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Case presentation
A 48-year-old Caucasian man presented to the Emergency 
Room with a 5-month history of involuntary movements of 
the limbs and confusion.
His past medical history was negative for epilepsy, cancer, 
traumas, previous surgery, and psychiatric disorders. Four 
months before this evaluation, the patient was admitted to 
the Neurological Unit for involuntary limb movements. Neu-
rological examination, electroencephalography (EEG), brain 
computed tomography (CT) scan and magnetic resonance 
imaging (MRI) were normal. Biochemical exams showed 
a moderate hyponatremia (129 mmol/L) that responded to 
fluid restriction. Psychiatric assessment led to the diagnosis 
of conversion disorder with comorbid anxiety. Clonazepam 
was prescribed, but his symptoms did not improve. Spe-
cifically, the patient reported sudden and brief episodes of 
involuntary limb movements, predominantly jerking of the 
arms, without incontinence or loss of consciousness. These 
episodes occurred several times a day, and they were often 
followed by minor falls. There was no obvious trigger, but 
he felt strange prior to the events. His wife noticed that he 
was confused, had poor memory, pronounced context-inap-
propriate sentences and had dramatically changed his behav-
ior and personality. He denied headache, weight loss, fever, 
fatigue, pain, and gastrointestinal/pulmonary symptoms.
The patient was physically active, did not smoke, and 
denied exposure to heavy metals/toxic agents, alcohol 
assumption, and use of illicit drugs. His only medication 
was clonazepam, and he was not on diuretics. He was under 
pressure for work- and family-related problems, as he was 
the owner of a pet shop and also had to look after his father 
with Alzheimer’s disease and his brother with schizophrenia.
Physical and neurological examinations were nor-
mal. Routine blood tests (Table 1) revealed hyponatremia 
(126 mmol/L) and increased creatine kinase levels (481 
UI/L). EEG showed minimal non-specific abnormalities, 
and brain CT scan was normal.
Drs. Bernardi, Arietti, Scandella, Gargiulo, Papa, 
and Beccuti (Internists)
We first explored the potential causes of hyponatremia. 
Serum osmolarity was 248 mOsm/Kg, confirming hypotonic 
hyponatremia. At the physical examination, there were no 
signs of peripheral edema, ascites, and hypovolemia; hema-
tocrit was in the lower normal range, indicating euvolemia. 
Urine osmolarity was markedly elevated (797 mOsm/Kg), 
excluding the possibility of psychogenic polydipsia. Uric 
acid was abnormally low, while thyroid hormones, TSH, 
and serum cortisol were normal. Based on these findings, 
we suspected a syndrome of inappropriate antidiuretic 
hormone secretion (SIADH). Although, hyponatremia can 
cause forgetfulness, confusion, and even seizures, neuropsy-
chiatric symptoms were unlikely due to hyponatremia as the 
decrease in serum sodium concentration was mild. Moreo-
ver, abnormal movements were still witnessed after hypona-
tremia resolution with fluid restriction.
Given the absence of abnormalities at the neurologi-
cal examination, on EEG and brain CT scan, his seizures 
were likely non-epileptic psychogenic. Consistent with this 
hypothesis, video-EEG and MRI did not show any alteration. 
However, the differential diagnosis of a conversion disorder 
includes various neurologic diseases, and we should be cau-
tious in formulating a diagnosis of conversion disorder, even 
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if concurrent stress conditions may suggest it. Indeed, neu-
rologic diseases may present with unusual features. Moreo-
ver, a normal EEG does not exclude the diagnosis of focal 
seizure activity, particularly if the area of irritability is small 
and deeply placed.
Other abnormalities were found in our patient. The neu-
ropsychological tests showed a deficit of attention and short-
term memory, with a poor performance on the Backward 
Digit Span and the Ray-15 Item Memory tests. In addition, 
there was a drop of 50 mmHg in systolic blood pressure 
from lying to standing, and non-invasive autonomic test-
ing confirmed severe autonomic dysfunction with impaired 
sympathetic skin response.
Drs. Gruden, Bernardi, Cavallo Perin, Durazzo 
(Internists), and Rizzone (Neurologist)
The patient had a subacute onset of cognitive dysfunction, 
dysautonomia, psychiatric disturbances, involuntary move-
ments, and SIADH. Taken together, these abnormalities 
suggested a neurological rather than a psychiatric underly-
ing cause. Neurodegenerative, infective, and autoimmune 
etiologies appeared the most likely causes of the subacute 
cognitive dysfunction; therefore, a panel of serological tests 
and a lumbar puncture were scheduled.
Cerebrospinal fluid (CSF) was limpid, glucose and leu-
cocytes in the normal range and proteins mildly elevated. 
Markers of dementia (amyloid β, protein 14.3.3, total Tau 
and phosphorylated Tau) and multiple sclerosis (isoelec-
tric focusing analysis and Link index) were negative. Oli-
goclonal bands were absent, and IgG slightly elevated. 
Both serum and CSF testing for bacterial, viral, and prion 
infections were negative (Table 2).
Serum antibodies against leucine-rich glioma-inacti-
vated 1 (LGI1) were detected at high titer (1:10,000, nor-
mal < 1:10), while other autoimmune encephalitis antibod-
ies (NMDA, AMPA, CASPR2, GABA-B receptor) were 
absent. LGI1 antibodies are the hallmark of a subtype of 
autoimmune encephalitis, named autoimmune encephalitis 
with LGI1 antibodies (LGI1-AIE). LGI1-AIE is character-
ized by the subacute onset of cognitive decline, psychiatric 
disturbances, and seizures, and is often associated with 
SIADH. Therefore, the patient had all the clinical features 
of LGI1-AIE, except for the lack of MRI abnormalities. 
However, brain 18F-fluoro-2-deoxy-d-glucose positron 
emission tomography/computerized tomography (FDG-
PET/CT) scan showed a mild asymmetry with a greater 
uptake in the right temporal–mesial area compared to the 
left.
Table 1  Laboratory data Variable Reference range On presentation
Hemoglobin (g/dL) 13.5–18.0 13.6
Hematocrit (%) 40.0–52.0 40.1
White Blood Count (per  mm3) 4000–10,000 7340
Platelet count (per  mm3) 140,000–450,000 368,000
Sodium (mmol/L) 135–145 126
Potassium (mmol/L) 3.5–5.0 4.5
Calcium (mmol/L) 2.2–2.6 2.26
Serum Creatinine (mg/dL) 0.60–1.30 0.79
Serum Glucose (mg/dL) 70–109 101
Alanine aminotransferase (U/L) 8–45 27
Aspartate aminotransferase (U/L) 8–40 29
Creatine kinase (U/L) 25–190 481
Lactate dehydrogenase (U/L) 250–450 582
Prothrombin time INR 0.85–1.25 1.11
Activated partial prothrombin time (ratio) 0.8–1.18 0.88
Fibrinogen (mg/dL) 200–400 367
C-reactive protein (mg/L) < 5 0.9
Thyroid-stimulating hormone (μU/mL) 0.270–4.200 2.37
Free triiodothyronine-(pg/mL) 2.6–4.4 2.8
Free thyroxine-fT4 (pg/mL) 9.3–17.0 10.6
Morning cortisol (mcg/L) 62–194 95.9
Serum osmolarity (mOsm/kg) 278–305 248
Urinary osmolarity (mOsm/kg) 50–1400 797
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Drs. Gruden, Bernardi, Scandella, Arietti, Gargiulo, 
Papa, Beccuti, and Cavallo Perin (Internists)
LGI1-AIE can be associated with occult cancer, as well as 
autonomic cardiac dysfunction. However, whole-body CT 
and PET scans showed no evidence of malignancy. Moreo-
ver, Holter monitor ECG and 123I metaiodobenzylguanidine 
myocardial scintigraphy were normal.
Drs. Gruden, Durazzo (Internists), Rizzone 
(Neurologist), and Villari (Psychiatrist)
The patient was treated with methylprednisolone (1 g/day 
intravenous for 5 days followed by oral prednisone 50 mg 
and subsequent slow tapering) and intravenous immuno-
globulins (IVIG 0.4 g/kg/day for 5 days). Under steroid 
treatment, the patient developed psychosis with persecu-
tory delusions and visual hallucinations. After attempting 
suicide by self-defenestration, olanzapine was introduced, 
and the patient transferred to the psychiatric ward. Psy-
chotic symptoms gradually subsided, and the patient was 
discharged from hospital. A neurological follow-up and a 
plasma exchange (PLEX) session were planned in the Out-
patient Service.
Drs. Rizzone (Neurologist) and Villari (Psychiatrist)
After being discharged from hospital, the patient developed 
manic episodes. Olanzapine dose was increased to 15 mg/
day, azathioprine was added as steroid sparing agent, and 
the patient underwent further PLEX sessions and IVIG infu-
sions. Patient symptoms progressively improved, so olan-
zapine and corticosteroids were slowly discontinued. At the 
last follow-up visit (20 months after hospital admission), the 
patient was completely asymptomatic, though LGI1 antibod-
ies were still detectable in serum at low titers (1:10). He was 
maintained on a low dose of azathioprine (100 mg) with 
follow-up visits scheduled every 6 months.
Discussion
Autoimmune encephalitis (AIE) syndromes are rare, but 
increasingly recognized causes of encephalitis. They are due 
to autoantibodies against surface or synaptic neuronal pro-
teins [1]. Our patient had a subtype of AIE that is character-
ized by the presence of autoantibodies against LGI1. These 
autoantibodies disrupt pre- and post-synaptic LGI1 sign-
aling, leading to neuronal hyper-excitability [2]. Because 
LGI1 is mainly present in the hippocampus and the temporal 
cortex, the disease presents as limbic encephalitis [3].
LGI1-AIE represents the second most common type of 
autoimmune encephalitis with an incidence rate of 0.83 
cases per 1 million people [4, 5]. It usually affects sub-
jects older than 40 years with a male predominance and is 
strongly associated with HLA-DR7 and HLA-DRB4 [1, 6, 
7]. A possible triggering factor of immune-mediated enceph-
alitis is cancer [8]. However, at variance with paraneoplastic 




 Bacterial culture – Negative














 Real time polymerase chain reaction JCV DNA Negative
 Chemiluminescence Immunoassay Borrelia Burgdorferi IgG (U/mL) < 5.5
Borrelia Burgdorferi IgM (U/mL) < 3.5
Rickettsia Conorii IgG < 0.9
Rickettsia Conorii IgM < 0.9
Treponema pallidium Ab < 0.1
HIV p24 antigen Negative
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encephalitis, AIE may occur either in the presence or in the 
absence of cancer, and LGI1-AIE is rarely associated with 
malignancy, though cases of thymoma and lung cancer 
have been reported [1, 8, 9]. We performed whole-body CT 
and PET scans to exclude the presence of an occult tumor. 
Moreover, long-term follow-up was planned, as tumors can 
become detectable years after encephalitis onset [9].
LGI1-AIE diagnosis is very challenging, and the median 
delay to initiation of immunotherapy is over 3 months [10]. 
Clinical characteristics suggestive of encephalitis, such as 
headache and hyperthermia, are absent, and symptoms can 
be misleading. Indeed, on one hand, our patient’s family his-
tory of schizophrenia and the presence of both anxiety and 
odd limb movements suggested a psychiatric disorder; on the 
other hand, confusion, memory loss, and cognitive deficits 
suggested an early neurodegenerative disease.
Focal seizures were helpful in making the diagnosis, as 
faciobrachial dystonic seizures (FBDS) are pathognomonic 
of LGI1-AIE [3, 11]. FBDS consist of frequent and brief 
abnormal jerk movements involving the arm and the ipsilat-
eral face and less frequently the leg. Notably, FBDS onset 
normally precedes the development of cognitive dysfunc-
tion. Thus, in our patient, treatment with immunotherapy 
at the first hospital admission would have probably pre-
vented the development of cognitive impairment [1, 11, 
12]. Another important diagnostic clue was the presence 
of SIADH. The binding of anti-LGI1 antibodies to hypo-
thalamic neurons expressing both LGI1 and ADH causes 
increased ADH secretion; in fact, 65% of people with LGI1-
AIE have also hyponatremia [8, 13].
Dysautonomia develops in 23% of subjects with LGI1-
AIE, but it is not specific and can be seen in other AIE. 
Symptoms are usually mild and include postural hypoten-
sion, diarrhea, and urinary dysfunction. The most frighten-
ing manifestation is autonomic cardiac dysfunction, possibly 
leading to severe bradycardia and sinus arrest. Therefore, 
this complication requires clinical vigilance; Holter ECG 
monitoring and myocardial scintigraphy are suggested to 
exclude cardiac involvement [13].
Further investigations, such as video-EEG, lumbar 
puncture, and MRI, may help in the differential diagnosis, 
but they are normal in a large proportion of LGI1-AIE 
patients. Normal video-EEG or with non-specific abnor-
malities is common in LGI1-AIE patients and do not rule 
out AIE diagnosis [9, 13]. CSF is unremarkable in 75% of 
LGI1-AIE patients, though a modest increase in protein 
levels is often found [9, 14]. Brain MRI is normal in 50% 
of LGI1-AIE cases, though the presence of medial tem-
poral lobe swelling with hyper-intensities on T2 and fluid 
attenuation inversion recovery (FLAIR) sequences is quite 
suggestive of the disease [11, 13]. Recently, 18-FDG-PET/
CT has also been proposed for the diagnosis of LGI1-AIE 
[15]. Small studies have shown abnormalities in LGI1-AIE 
patients, such as asymmetric hypermetabolism of basal 
ganglia and medial–temporal areas [16]. Consistent 
with this, we found asymmetry in the uptake of 18-FDG 
between left and right temporal–medial areas. Changes in 
brain metabolism appear to better correlate with clinical 
symptoms, severity, and response to immunotherapy com-
pared with structural MRI abnormalities [16]. However, 
further studies are required to establish whether 18-FDG-
PET/CT may be a valuable tool in LGI1-AIE diagnosis 
and monitoring.
The detection of LGI1 autoantibodies plays a key role 
in the diagnosis of LGI1-AIE. Clinicians should perform 
serological screening for AIE in all patients with subacute 
onset of psychiatric abnormalities, cognitive dysfunction, 
and FBDS with and without hyponatremia, even if EEG, 
CSF, and MRI are normal. Because sensitivity of anti-LGI1 
antibody measurement is greater in serum than in CSF 
[17], the measurement in CSF is not strictly required for 
the diagnosis.
The discovery of anti-neuronal autoantibodies in AIE, 
including LGI1, has generated a great deal of interest into 
the possibility that subgroups of patients with primary 
psychiatric disorders, such as schizophrenia, may have an 
autoantibody-mediated disease (autoimmune psychosis). 
Although fascinating, this hypothesis is supported by lim-
ited data. On the other hand, LGI1-AIE can be misdiagnosed 
as a psychotic disorder, and it is of paramount importance 
to increase awareness of LGI1-AIE among both psychia-
trists and internists to avoid diagnostic delay or incorrect 
diagnosis.
Our patient was treated with corticosteroids, IVIG, and 
PLEX that are the recommended first-line therapies in 
patients with LGI1-AIE [3, 15, 18]. As corticosteroids can 
exacerbate psychosis, azathioprine can be added as steroid 
sparing agent [3]. Treatment was started immediately, as 
early therapy is associated with better outcomes and fewer 
relapses [8]. Overall response rate to first-line therapy is 
around 70%, though fluctuations and relapses are frequent 
[9].
A full clinical recovery was observed in our patient; how-
ever, anti-LGI1 antibodies were still detectable in serum 
more than a year after presentation. This is not surprising, 
as anti-LGI1 autoantibody levels correlate poorly with the 
course of the disease and remain positive up to 2 years after 
clinical recovery [1, 9, 18]. Prognosis is usually benign in 
responders; however, most patients show mild memory and 
cognitive impairment after long-term follow-up, particularly 
in the absence of early and appropriate immunotherapy [19]. 
In non-responders, rituximab and cyclophosphamide are 
used as the second-line agents, with the former having the 
least side effects [11]. Recently, bortezomib and antibod-
ies against IL-2 and IL-6 have been proposed as alternative 
second-line treatment [18].
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In conclusion, herein, we present a case of LGI1-AIE 
that was first misdiagnosed as conversion disorder. Despite 
the absence of CSF, EEG, and MRI abnormalities, we diag-
nosed LGI1-AIE based on typical clinical features and the 
detection of autoantibodies. Our clinical case underlies the 
importance of maintaining a high level of clinical suspicion 
of LGI1-AIE to avoid delayed diagnosis or misdiagnosis.
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